SEARCH

SEARCH BY CITATION

Abstract

  1. Top of page
  2. Abstract
  3. EXTENDED CRITERIA IN THE UNCOMPLICATED PATIENT
  4. EXTENDED CRITERIA FOR AGE
  5. EXTENDED CRITERIA FOR HCC
  6. EXTENDED CRITERIA FOR NON-HCC HEPATIC MALIGNANCIES
  7. EXTENDED CRITERIA FOR PPH AND HPS
  8. EXTENDED CRITERIA FOR ALD
  9. EXTENDED CRITERIA FOR HIV INFECTIONS
  10. EXTENDED CRITERIA FOR STRUCTURAL NONHEPATIC DISEASE [PARTICULARLY CORONARY ARTERY DISEASE (CAD)]
  11. EXTENDED SOCIOECONOMIC CRITERIA
  12. EXTENDED CRITERIA FOR NARCOTIC ADDICTION
  13. SUMMARY AND CONCLUSIONS: HOW CAN WE OVERCOME THESE IMPEDIMENTS AND BARRIERS FOR EXTENDED CRITERIA PATIENTS?
  14. REFERENCES

Key Points

1. There is an increasing recognition that previously marginal candidates for liver transplantation can receive therapies that allow transplant to take place.

2. Coronary artery disease is an increasing co-morbidity in liver transplant candidates.

3. Physio-social issues require written guidelines and patient advocates.

4. Methadone maintenance therapy per se is not a contra-indication to liver transplantation. Liver Transpl 18:S-S, 2012. © 2012 AASLD.

The terms extended criteria and marginal could be exchanged with terms such as borderline and unprofitable, and in the setting of liver transplantation, they imply that the outcomes for such patients will be significantly worse than expected. The use of the terms extended criteria and marginal implies that there are well-established criteria for the selection of liver transplant recipients in the first place. Indeed, such criteria do exist. Organizations such as the American Association for the Study of Liver Diseases and the Transplantation Society of Australia and New Zealand1, 2 have recipient criteria for liver transplantation that range from the general to the specific; for example, patients with chronic liver failure due to cirrhosis generally qualify for liver transplantation on the basis of Model for End-Stage Liver Disease (MELD) scores and/or specific complications resistant to current therapies (eg, a MELD score > 15 and/or resistant ascites/encephalopathy). Specific criteria are applied to patients with hepatocellular cancer (HCC), portopulmonary hypertension (PPH), hepatopulmonary syndrome (HPS), alcoholic liver disease (ALD), and human immunodeficiency virus (HIV) coinfections. In addition to such criteria, patients should not have significant extrahepatic diseases that cannot be reversed by transplantation and that consequently may impair optimal outcomes. Finally, patients are expected to have stable psychosocial situations and be able to cope with the stresses and strains of the transplant process for many years.

Transplant patients meeting these criteria have well-accepted outcomes after liver transplantation with 1-, 5-, and 10-year survival rates of 90%, 75%, and 60%, respectively.3-5 This article discusses where and when recipient criteria can be extended with acceptable outcomes still being maintained.

EXTENDED CRITERIA IN THE UNCOMPLICATED PATIENT

  1. Top of page
  2. Abstract
  3. EXTENDED CRITERIA IN THE UNCOMPLICATED PATIENT
  4. EXTENDED CRITERIA FOR AGE
  5. EXTENDED CRITERIA FOR HCC
  6. EXTENDED CRITERIA FOR NON-HCC HEPATIC MALIGNANCIES
  7. EXTENDED CRITERIA FOR PPH AND HPS
  8. EXTENDED CRITERIA FOR ALD
  9. EXTENDED CRITERIA FOR HIV INFECTIONS
  10. EXTENDED CRITERIA FOR STRUCTURAL NONHEPATIC DISEASE [PARTICULARLY CORONARY ARTERY DISEASE (CAD)]
  11. EXTENDED SOCIOECONOMIC CRITERIA
  12. EXTENDED CRITERIA FOR NARCOTIC ADDICTION
  13. SUMMARY AND CONCLUSIONS: HOW CAN WE OVERCOME THESE IMPEDIMENTS AND BARRIERS FOR EXTENDED CRITERIA PATIENTS?
  14. REFERENCES

Extended criteria in this setting include the consideration of liver transplantation for patients with MELD scores < 15 and for patients with very high MELD scores. First, let us consider patients with low MELD scores. The data suggest that the short-term (12-month) survival benefit of liver transplantation does not come into effect until the MELD score reaches approximately 16.6 However, this drops if the 5-year survival benefit is taken into account.7, 8 The major limitation of trekking this ground is the lack of deceased donor organs: even if such patients were offered liver transplantation, they would be competing with patients with higher MELD scores and thus would not be allocated donor organs. There has been much discussion about whether such patients should be listed and be allocated marginal donor organs not suitable for other recipients. An analysis of this practice has led to the conclusion that this is not a good idea, and survival benefits will not be seen.9 The alternative of steering these patients to available living donors has been proposed. Indeed, a recent analysis has suggested survival benefits for non-HCC patients with MELD scores < 15.10

When the MELD system was introduced, it was expected that patients with very high MELD scores (eg, >40) would in fact have worse outcomes. However, in the United States, this generally has not been the case, and high MELD scores do not limit the survival benefits of liver transplantation.7 However, poor outcomes have been observed, particularly at European centers.11 The transplant community continues to struggle with this, but there are currently no established criteria that define futility on the basis of MELD scores; however, a recent abstract suggests that patients who are ventilator-dependent, require dialysis, and are on inotropes do very poorly.12

A well-recognized consideration for the uncomplicated patient is malnutrition. This is associated with worse outcomes after transplantation.13, 14 Studies have addressed the issue of reduced muscle mass and sarcopenia in patients with end-stage cirrhosis.15, 16 A recent review recommends muscle strength training via exercise as a means of improving muscle mass with the potential to improve posttransplant outcomes.16

EXTENDED CRITERIA FOR AGE

  1. Top of page
  2. Abstract
  3. EXTENDED CRITERIA IN THE UNCOMPLICATED PATIENT
  4. EXTENDED CRITERIA FOR AGE
  5. EXTENDED CRITERIA FOR HCC
  6. EXTENDED CRITERIA FOR NON-HCC HEPATIC MALIGNANCIES
  7. EXTENDED CRITERIA FOR PPH AND HPS
  8. EXTENDED CRITERIA FOR ALD
  9. EXTENDED CRITERIA FOR HIV INFECTIONS
  10. EXTENDED CRITERIA FOR STRUCTURAL NONHEPATIC DISEASE [PARTICULARLY CORONARY ARTERY DISEASE (CAD)]
  11. EXTENDED SOCIOECONOMIC CRITERIA
  12. EXTENDED CRITERIA FOR NARCOTIC ADDICTION
  13. SUMMARY AND CONCLUSIONS: HOW CAN WE OVERCOME THESE IMPEDIMENTS AND BARRIERS FOR EXTENDED CRITERIA PATIENTS?
  14. REFERENCES

Most centers do not restrict transplantation on the basis of age alone, although it seems that an age beyond 70 years may be considered an extended criterion. Acceptable results for the transplantation of carefully selected patients older than 70 years have been well reported, although the overall survival rate is lower than that for younger patients.17, 18 Some authors have used an older recipient prognostic score to stratify patients; this score includes factors such as the ventilation status, the diabetes mellitus status, a serum creatinine level > 160 μmol/L, and a combined donor and recipient age > 120 years.19 When this score was >2, the 5-year survival rate was only 50%. Recently, the outcomes of patients undergoing transplantation for HCC at ages > 70 years have been reported.20, 21 Survival was lower for these patients versus younger patients, but unlike patients < 70 years old, the survival of older patients was not affected by the existence of HCC.20 The authors concluded that patients older than 70 years should not be denied liver transplantation. This approach, however, was questioned in an accompanying editorial.21 Perkins21 pointed out that survival was superior in the elderly with HCC who underwent local ablation rather than liver transplantation, although it is likely that tumor-free survival would be lower. It seems reasonable for patients older than 70 years to undergo transplantation, but careful selection is warranted with respect to nonhepatic comorbidities and small HCCs that are amendable to ablation.

EXTENDED CRITERIA FOR HCC

  1. Top of page
  2. Abstract
  3. EXTENDED CRITERIA IN THE UNCOMPLICATED PATIENT
  4. EXTENDED CRITERIA FOR AGE
  5. EXTENDED CRITERIA FOR HCC
  6. EXTENDED CRITERIA FOR NON-HCC HEPATIC MALIGNANCIES
  7. EXTENDED CRITERIA FOR PPH AND HPS
  8. EXTENDED CRITERIA FOR ALD
  9. EXTENDED CRITERIA FOR HIV INFECTIONS
  10. EXTENDED CRITERIA FOR STRUCTURAL NONHEPATIC DISEASE [PARTICULARLY CORONARY ARTERY DISEASE (CAD)]
  11. EXTENDED SOCIOECONOMIC CRITERIA
  12. EXTENDED CRITERIA FOR NARCOTIC ADDICTION
  13. SUMMARY AND CONCLUSIONS: HOW CAN WE OVERCOME THESE IMPEDIMENTS AND BARRIERS FOR EXTENDED CRITERIA PATIENTS?
  14. REFERENCES

A recent global consensus conference on liver transplantation for HCC concluded that “the Milan criteria are currently the benchmark for the selection of non HCC patients for liver transplantation, and the basis for comparison with other suggested criteria.”22 Moreover, “a modest expansion of the number of potential candidates may be considered on the basis of several studies showing comparable survival for patients outside the Milan criteria.”22 Thus, it seems that individual centers in different parts of the world do perform transplantation outside the standard Milan criteria. There is much literature on this topic, which has been summarized by Germani et al.23 It seems that the tumor size may be more important than the tumor number in predicting recurrence along with high alpha-fetoprotein levels (>1000 ng/mL).

Extended criteria also include down-staging. The consensus conference also concluded that “transplantation may be considered after successful downstaging … but … should achieve a 5-year survival comparable to that of HCC patients who meet the criteria for liver transplantation without requiring downstaging.”22

Thus, the trekking of new ground in HCC seems to be very fluid, geographically dependent, and under constant scrutiny with respect to outcomes. Also, the issue of immunosuppression for HCC remains under regular review with great interest in the use of mammalian target of rapamycin inhibitors.24

EXTENDED CRITERIA FOR NON-HCC HEPATIC MALIGNANCIES

  1. Top of page
  2. Abstract
  3. EXTENDED CRITERIA IN THE UNCOMPLICATED PATIENT
  4. EXTENDED CRITERIA FOR AGE
  5. EXTENDED CRITERIA FOR HCC
  6. EXTENDED CRITERIA FOR NON-HCC HEPATIC MALIGNANCIES
  7. EXTENDED CRITERIA FOR PPH AND HPS
  8. EXTENDED CRITERIA FOR ALD
  9. EXTENDED CRITERIA FOR HIV INFECTIONS
  10. EXTENDED CRITERIA FOR STRUCTURAL NONHEPATIC DISEASE [PARTICULARLY CORONARY ARTERY DISEASE (CAD)]
  11. EXTENDED SOCIOECONOMIC CRITERIA
  12. EXTENDED CRITERIA FOR NARCOTIC ADDICTION
  13. SUMMARY AND CONCLUSIONS: HOW CAN WE OVERCOME THESE IMPEDIMENTS AND BARRIERS FOR EXTENDED CRITERIA PATIENTS?
  14. REFERENCES

The 2 main areas of discussion are neuroendocrine tumors that have metastasized to the liver and cholangiocarcinoma. An analysis of the United Network for Organ Sharing database indicates that acceptable 5-year survival in the modern era can be achieved in patients with neuroendocrine tumors as long as patients are carefully selected.25

Worse survival was seen in patients with worse liver function (according to serum bilirubin and albumin levels). Also, elevated serum creatinine levels in donors seemed to affect outcomes.

The only trekking of new ground in cholangiocarcinoma has been the development more than 10 years ago of a pretransplant protocol that includes radiation/local chemotherapy and is designed to select patients less likely to experience posttransplant recurrence.26 More recent reports are available,27, 28 and experience from other centers supports the idea that acceptable results can be achieved with the careful selection of patients.29 The use of such protocols has led to established criteria that are accepted by the United Network for Organ Sharing and allow these patients to undergo liver transplantation.

EXTENDED CRITERIA FOR PPH AND HPS

  1. Top of page
  2. Abstract
  3. EXTENDED CRITERIA IN THE UNCOMPLICATED PATIENT
  4. EXTENDED CRITERIA FOR AGE
  5. EXTENDED CRITERIA FOR HCC
  6. EXTENDED CRITERIA FOR NON-HCC HEPATIC MALIGNANCIES
  7. EXTENDED CRITERIA FOR PPH AND HPS
  8. EXTENDED CRITERIA FOR ALD
  9. EXTENDED CRITERIA FOR HIV INFECTIONS
  10. EXTENDED CRITERIA FOR STRUCTURAL NONHEPATIC DISEASE [PARTICULARLY CORONARY ARTERY DISEASE (CAD)]
  11. EXTENDED SOCIOECONOMIC CRITERIA
  12. EXTENDED CRITERIA FOR NARCOTIC ADDICTION
  13. SUMMARY AND CONCLUSIONS: HOW CAN WE OVERCOME THESE IMPEDIMENTS AND BARRIERS FOR EXTENDED CRITERIA PATIENTS?
  14. REFERENCES

It is generally agreed that patients with a mean pulmonary artery pressure (PAP) > 40 mm Hg should not undergo liver transplantation.30 The trekking of new ground in this situation is confined to transplantation for patients with severe PPH who successfully undergo pressure-lowering therapies to decrease PAP to <35 mm Hg. This seems reasonable, although the numbers reported so far are relatively limited.31

There does not seem to be an absolute partial pressure of arterial oxygen (PaO2) that should deny the HPS patient liver transplantation.32 However, performing transplantation in patients with a PaO2 < 50 mm Hg and an estimated shunt > 20% seems hazardous.33 Such patients tend to remain hypoxic after transplantation, not come off the ventilator, and die within weeks of transplantation.

EXTENDED CRITERIA FOR ALD

  1. Top of page
  2. Abstract
  3. EXTENDED CRITERIA IN THE UNCOMPLICATED PATIENT
  4. EXTENDED CRITERIA FOR AGE
  5. EXTENDED CRITERIA FOR HCC
  6. EXTENDED CRITERIA FOR NON-HCC HEPATIC MALIGNANCIES
  7. EXTENDED CRITERIA FOR PPH AND HPS
  8. EXTENDED CRITERIA FOR ALD
  9. EXTENDED CRITERIA FOR HIV INFECTIONS
  10. EXTENDED CRITERIA FOR STRUCTURAL NONHEPATIC DISEASE [PARTICULARLY CORONARY ARTERY DISEASE (CAD)]
  11. EXTENDED SOCIOECONOMIC CRITERIA
  12. EXTENDED CRITERIA FOR NARCOTIC ADDICTION
  13. SUMMARY AND CONCLUSIONS: HOW CAN WE OVERCOME THESE IMPEDIMENTS AND BARRIERS FOR EXTENDED CRITERIA PATIENTS?
  14. REFERENCES

It is generally accepted that the main criteria for ALD revolve around abstinence from alcohol in the short and long terms. The standard rule is 6 months of abstinence before listing, although this has been strongly criticized.34 The criticism is largely based on the idea that abstinence for 6 months does not predict long-term survival for patients with ALD, although it does predict a return to heavy drinking. As a result of this dilemma, carefully selected patients with alcoholic hepatitis were selected for transplantation in a recent French study.35 Extended criteria transplantation was restricted to patients with an initial presentation of ALD and a Maddrey score > 32 who failed to respond to a 7-day course of corticosteroid therapy and whose psychosocial issues the care team universally agreed could be addressed. The results indicated 12-month posttransplant survival rates of 78% for these patients and 28% for historical matched controls. It should be recognized that only 2% of the patients with alcoholic hepatitis fulfilled the extended criteria.

EXTENDED CRITERIA FOR HIV INFECTIONS

  1. Top of page
  2. Abstract
  3. EXTENDED CRITERIA IN THE UNCOMPLICATED PATIENT
  4. EXTENDED CRITERIA FOR AGE
  5. EXTENDED CRITERIA FOR HCC
  6. EXTENDED CRITERIA FOR NON-HCC HEPATIC MALIGNANCIES
  7. EXTENDED CRITERIA FOR PPH AND HPS
  8. EXTENDED CRITERIA FOR ALD
  9. EXTENDED CRITERIA FOR HIV INFECTIONS
  10. EXTENDED CRITERIA FOR STRUCTURAL NONHEPATIC DISEASE [PARTICULARLY CORONARY ARTERY DISEASE (CAD)]
  11. EXTENDED SOCIOECONOMIC CRITERIA
  12. EXTENDED CRITERIA FOR NARCOTIC ADDICTION
  13. SUMMARY AND CONCLUSIONS: HOW CAN WE OVERCOME THESE IMPEDIMENTS AND BARRIERS FOR EXTENDED CRITERIA PATIENTS?
  14. REFERENCES

The current criteria for patients living with HIV who require liver transplantation for liver failure [usually hepatitis C virus (HCV)–related] include controlled HIV viremia, CD4 counts > 100 × 109/L, and no current opportunist infections.1 Extended criteria may lead to the inclusion of patients who have HIV viremia because of an intolerance of antiviral therapy rather than virological failure. Also, patients with acute HIV and liver failure may be considered candidates when there is no time to control the HIV infection. In both situations, it would be expected that alternative or newly instigated highly acute retroviral therapy would control HIV viremia after transplantation. It should be noted that in some centers, the outcomes of HCV/HIV-coinfected patients after transplantation have been poor despite the performance of transplantation within established criteria; this has provoked some debate about ways to improve outcomes for these patients.36, 37

EXTENDED CRITERIA FOR STRUCTURAL NONHEPATIC DISEASE [PARTICULARLY CORONARY ARTERY DISEASE (CAD)]

  1. Top of page
  2. Abstract
  3. EXTENDED CRITERIA IN THE UNCOMPLICATED PATIENT
  4. EXTENDED CRITERIA FOR AGE
  5. EXTENDED CRITERIA FOR HCC
  6. EXTENDED CRITERIA FOR NON-HCC HEPATIC MALIGNANCIES
  7. EXTENDED CRITERIA FOR PPH AND HPS
  8. EXTENDED CRITERIA FOR ALD
  9. EXTENDED CRITERIA FOR HIV INFECTIONS
  10. EXTENDED CRITERIA FOR STRUCTURAL NONHEPATIC DISEASE [PARTICULARLY CORONARY ARTERY DISEASE (CAD)]
  11. EXTENDED SOCIOECONOMIC CRITERIA
  12. EXTENDED CRITERIA FOR NARCOTIC ADDICTION
  13. SUMMARY AND CONCLUSIONS: HOW CAN WE OVERCOME THESE IMPEDIMENTS AND BARRIERS FOR EXTENDED CRITERIA PATIENTS?
  14. REFERENCES

It is generally accepted (Table 1) that patients with advanced respiratory or neurological diseases or established and untreatable infections that affect liver transplant outcomes are not considered candidates for transplantation. Exceptions include patients with respiratory diseases fulfilling the criteria for lung transplantation (eg, cystic fibrosis), for whom combined lung and liver transplantation has been successfully performed.38 The issues of diabetes mellitus and obesity are covered elsewhere in this issue of the journal,39 whereas the criteria for combined liver and kidney transplantation have been extensively discussed.40

However, an increasingly difficult topic is established CAD. In the early days of liver transplantation, it was thought that patients with advanced liver disease were relatively protected from CAD because of the associated hyperdynamic hemodynamics with low systemic resistance and relatively low blood pressures.41 However, because of the increasing frequency of obesity and nonalcoholic steatohepatitis and the association of HCV with insulin resistance, patients with established chronic liver failure are increasingly being found to have varying degrees of CAD. The prevalence of significant CAD (>70% stenosis) has been estimated to be 20% to 30% in several studies.42 In 1 study,43 such patients had a 50% mortality rate in the first 35 days after transplantation. Furthermore, in the long term, CAD is a major cause of nonhepatic mortality.

There is no doubt that the trekking of new ground for patients with CAD is currently ongoing, although no formal guidelines currently exist. Patients with mild CAD are not an issue, and those with advanced CAD who cannot undergo any revascularization therapies are clearly not candidates unless combined heart and liver transplantation is undertaken (there are no published series on combined transplantation for CAD and chronic liver failure). The main issue is inbetweeners: patients with single left anterior descending lesions or double/triple vessel disease for whom revascularization is possible.

Before these issues are discussed, there is much contention about how potential liver transplant recipients should be screened in the first place.44-46 Negative dopamine stress echocardiography findings are reasonably predictive of a low risk for significant CAD, but the test has poor positive predictive values. Thus, some authors have recommended immediately performing coronary angiography in patients with more than 2 known high-risk factors (eg, diabetes, obesity, a heavy smoking history, and an age > 50 years), although current cardiac society guidelines do not recommend this.47

Once significant CAD (>70% stenosis) is discovered in patients for whom revascularization is possible, there is an increasing view that stents should be inserted before transplantation, although there is no real evidence that this is beneficial for asymptomatic patients with respect to survival outcomes.47 Bare metal stents without dual platelet therapy (aspirin rather than clopidogrel) seem to be the current preference.47 If there is considerable ventricular dysfunction at this stage, such procedures will need to be monitored to establish reversibility. These practices seem reasonable, although only a relatively small number of patients have been reported in the literature.47 Such approaches should enable extended criteria patients to successfully undergo transplantation. The use of anticoagulation before and immediately after transplantation to maximize stent patency remains a challenge.

The management of the patient with established CAD who requires coronary artery graft (CAG) surgery is more complicated.48 There seem to be 4 options: (1) preoperative surgery, (2) a combined procedure at the time of liver transplantation, (3) postoperative CAG, or (4) combined heart and liver transplantation. Option 1 seems hazardous with unacceptable mortality (>50%) in patients with child pugh score B, whereas option 3 still puts the patient at risk of intraoperative and early postoperative mortality and morbidity. Option 4 would usually be reserved for patients with CAD and overt cardiac failure, but as mentioned previously, there do not seem to be reports of combined liver and cardiac surgery for these patients. Success with option 2 has been reported.48 Thus, the trekking of new ground for patients with CAD could include preoperative stenting and, if that is not possible, combined CAG surgery and liver transplantation. Of course, long-term postoperative management of cardiac risk is essential (Table 1).

Table 1. Options in Patients With CAD
  1. NOTE: This table is based on Carey et al.,42 Plotkin et al.,43 Findlay,44 Raval et al.,45 Ehtisham et al.,46 Azarbal et al.,47 Raichlin et al.,48 Gardner and Gibbs,49 Torregrosa et al.,50 Bravo and Hage,51 and Hennessey et al.52

1. How should patients be screened?
 a. Every recipient should undergo resting echocardiography.
 b. Patients with risk factors should undergo dobutamine stress echocardiography.
 c. Patients with more than 2 risk factors should perhaps be directed to coronary angiography.
2. What should be done?
 a. For mild disease, optimize medical therapies.
 b. For stentable disease, use metallic stents with an aspirin cover.
 c. For severe, nonstentable disease, perform simultaneous CAG surgery and liver transplantation or combined heart and liver transplantation.

Although issues with CAD have received the most recent attention, other heart-related conditions may require management in liver transplant recipients. Very small numbers of patients with severe aortic valve disease have undergone simultaneous valve replacement and liver transplantation, although the increasing use of percutaneous procedures may make such procedures unnecessary.49 Patients who present with clinical cirrhotic cardiomyopathy usually are not considered transplant candidates; however, aggressive medical management, including beta-blockers and angiotensin-converting enzyme pathway inhibition, may improve left ventricular dysfunction.50 Likewise, aggressive medical management combined with the use of alcohol atrial septal ablation in patients with hypertrophic cardiomyopathy or a left ventricular outflow tract obstruction also may allow liver transplantation to proceed.51 As mentioned earlier, combined heart and liver transplantation has been reported, but it has been performed mainly for amyloid (not CAD).52

EXTENDED SOCIOECONOMIC CRITERIA

  1. Top of page
  2. Abstract
  3. EXTENDED CRITERIA IN THE UNCOMPLICATED PATIENT
  4. EXTENDED CRITERIA FOR AGE
  5. EXTENDED CRITERIA FOR HCC
  6. EXTENDED CRITERIA FOR NON-HCC HEPATIC MALIGNANCIES
  7. EXTENDED CRITERIA FOR PPH AND HPS
  8. EXTENDED CRITERIA FOR ALD
  9. EXTENDED CRITERIA FOR HIV INFECTIONS
  10. EXTENDED CRITERIA FOR STRUCTURAL NONHEPATIC DISEASE [PARTICULARLY CORONARY ARTERY DISEASE (CAD)]
  11. EXTENDED SOCIOECONOMIC CRITERIA
  12. EXTENDED CRITERIA FOR NARCOTIC ADDICTION
  13. SUMMARY AND CONCLUSIONS: HOW CAN WE OVERCOME THESE IMPEDIMENTS AND BARRIERS FOR EXTENDED CRITERIA PATIENTS?
  14. REFERENCES

There is obvious (Table 2) concern within liver transplant centers that certain patients, not defined by their medical status, may not be able to cope with the stresses and strains of the liver transplant process. Mental health issues, inadequate social support, and compliance may reflect this. Socioeconomic status is defined in the literature and is potentially measurable. It may be measured by scores based on levels of education, mean household incomes, and geographic locations.53, 54 However, actual data showing that socioeconomic status per se affects outcomes are equivocal. At least 1 study has suggested no effect, whereas others have indicated that a low socioeconomic status is associated with worse outcomes.55-57 It should be noted that 1 study found worse outcomes for patients who did not return to employment after transplantation, and socioeconomic status per se did not have a negative impact.56 However, that study indicated that returning to work after transplantation was linked to the employment status before transplantation (often a marker for a low socioeconomic status). In a recent study,57 a low mean household income was independently linked to mean fibrosis scores after transplantation in HCV-infected subjects. Thus, some data support the concept that socioeconomic status/psychosocial issues should be part of the assessment of an individual for liver transplantation because they may directly or indirectly affect outcomes.

This then begs the question whether socioeconomic status actually influences decisions about listing for liver transplantation. There is evidence that patients with a lower socioeconomic status (eg, African Americans) are listed with higher MELD scores than other patients.53, 54 Also, private health insurance was an independent predictor of liver transplant listing in 1 study.53

Socioeconomic status is also strongly linked to psychosocial barriers to transplantation, and it seems clear that both play roles in the process of listing patients for liver transplantation. Recent studies have tried to examine how such decisions are made by transplant centers.58, 59 Two-thirds of the studied centers used social barriers as a hindrance to listing for liver transplantation, but 50% of the centers had no formal evaluation tool for evaluating such barriers. These centers found that psychosocial barriers often led to “protracted and contentious discussion” within teams. The authors of the study recommended 2 strategies for minimizing prejudice and bias in such decision making: (1) the appointment of an independent patient advocate within the team and (2) documented written policies about exclusion/inclusion criteria for listing (Table 2).

Table 2. Psychosocial Issues
  1. NOTE: This table is based on Kemmer et al.,53 Kemmer and Neff,54 Yoo et al.,55 Hunt et al.,56 Verna et al.,57 Volk et al.,58 and Hogan et al.59

1. There is a correlation between psychosocial issues and low socioeconomic status.
2. There is evidence for discrimination in listing based on socioeconomic issues.
3. Socioeconomic status may not affect posttransplant outcomes.
4. The majority of centers make decisions on the basis of psychosocial considerations.
5. Psychosocial issues result in very prolonged discussions within transplant programs.
6. Definite transparent criteria and patient advocates should be introduced.

In conclusion, if socioeconomic/psychosocial criteria are used to exclude patients, then perhaps such decisions should be universal within the team and should be transparently communicated to patients and families alike (perhaps in a manner similar to that for accepting patients for transplantation with alcoholic hepatitis). The widespread adoption of such procedures would certainly trek new ground and potentially overcome some of the barriers that currently seem to be in place.

EXTENDED CRITERIA FOR NARCOTIC ADDICTION

  1. Top of page
  2. Abstract
  3. EXTENDED CRITERIA IN THE UNCOMPLICATED PATIENT
  4. EXTENDED CRITERIA FOR AGE
  5. EXTENDED CRITERIA FOR HCC
  6. EXTENDED CRITERIA FOR NON-HCC HEPATIC MALIGNANCIES
  7. EXTENDED CRITERIA FOR PPH AND HPS
  8. EXTENDED CRITERIA FOR ALD
  9. EXTENDED CRITERIA FOR HIV INFECTIONS
  10. EXTENDED CRITERIA FOR STRUCTURAL NONHEPATIC DISEASE [PARTICULARLY CORONARY ARTERY DISEASE (CAD)]
  11. EXTENDED SOCIOECONOMIC CRITERIA
  12. EXTENDED CRITERIA FOR NARCOTIC ADDICTION
  13. SUMMARY AND CONCLUSIONS: HOW CAN WE OVERCOME THESE IMPEDIMENTS AND BARRIERS FOR EXTENDED CRITERIA PATIENTS?
  14. REFERENCES

Most centers (Table 3) would exclude patients currently using intravenous drugs from liver transplantation.1 This probably reflects concerns about the chaotic nature of the lives of many patients in this situation and the likelihood of noncompliance with medical therapies and ongoing care. Although occasional intravenous drug use may be tolerated (though discouraged), the main discussion within the liver transplant community concerns patients on methadone maintenance programs. The majority of these patients have HCV as the cause of liver failure.

It is well established that, on average, patients with narcotic addictions who enter methadone maintenance programs have less chaotic lives, more stable social lives, and higher employment levels and are involved in fewer crime-related activities.60 It is also clear that when a patient is on such a program for a longer time, the likelihood of illicit opiate use decreases quite dramatically: by 10 years, fewer than 20% of patients use illicit opiates.60 Indeed, Koch and Banys60 stated that “the efficacy of methadone maintenance is one of the most over studied and over proven questions in all of addiction medicine.”

Thus, there is little rationale for routinely excluding patients in methadone maintenance programs. However, this seems not to be the case. In the past, methadone use alone has been used to exclude patients from liver transplant lists.61 Indeed, a survey performed 10 years ago indicated that only 56% of North American liver transplant units accepted patients on methadone, and 32% required the cessation of methadone use.61 When this became apparent, there was much discussion of the inappropriateness of such decisions.61 This coincided with the publication of several articles showing no survival differences between HCV-infected patients on methadone maintenance and patients not on methadone maintenance.52-64 It is recognized, however, that such patients may require increased use of pain-relieving therapies, particularly in the early postoperative period.64 It is important to use pain-relief protocols in conjunction with drug and alcohol specialists in the management of these patients in the early postoperative phase.

It is also clear that careful patient selection is required because returns to intravenous drug use on methadone maintenance have been reported after transplantation and are associated with increased noncompliance.

Nevertheless, the trekking of new ground for methadone patients really means not using methadone alone as a criterion for performing or not performing transplantation.65 Such patients may have increased medical and psychosocial issues, but these should be analyzed on their own merit, and methadone itself should not be used to determine inclusion (Table 3). This is in accordance with American Association for the Study of Liver Diseases practice guidelines.1

Table 3. Recommendations for Methadone Maintenance Patients
  1. NOTE: This table is based on Koch and Banys,60 Jiao et al.,61 Kanchana et al.,62 Liu et al.,63 Weinrieb et al.,64 and Hancock et al.65

1. It should be recognized that methadone is a therapy (not an addiction) and can stabilize patients' lives.
2. Psychosocial issues should be analyzed in their own right.
3. Patients should not be asked to come off methadone before transplantation.
4. Patients may require increased narcotic use after transplantation.
5. Patients should not be refused transplantation on the basis of methadone use alone.

SUMMARY AND CONCLUSIONS: HOW CAN WE OVERCOME THESE IMPEDIMENTS AND BARRIERS FOR EXTENDED CRITERIA PATIENTS?

  1. Top of page
  2. Abstract
  3. EXTENDED CRITERIA IN THE UNCOMPLICATED PATIENT
  4. EXTENDED CRITERIA FOR AGE
  5. EXTENDED CRITERIA FOR HCC
  6. EXTENDED CRITERIA FOR NON-HCC HEPATIC MALIGNANCIES
  7. EXTENDED CRITERIA FOR PPH AND HPS
  8. EXTENDED CRITERIA FOR ALD
  9. EXTENDED CRITERIA FOR HIV INFECTIONS
  10. EXTENDED CRITERIA FOR STRUCTURAL NONHEPATIC DISEASE [PARTICULARLY CORONARY ARTERY DISEASE (CAD)]
  11. EXTENDED SOCIOECONOMIC CRITERIA
  12. EXTENDED CRITERIA FOR NARCOTIC ADDICTION
  13. SUMMARY AND CONCLUSIONS: HOW CAN WE OVERCOME THESE IMPEDIMENTS AND BARRIERS FOR EXTENDED CRITERIA PATIENTS?
  14. REFERENCES

An attempt has been made in Table 4 to do this. Clearly, we can extend the benefits of liver transplantation to recipients who more than 10 years ago would have had established contraindications to transplantation. In order to achieve this in an era of decreasing availability of deceased donor organs and increasing individual entitlement associated with increasing accountability and transparency, we need to establish processes by which the current extended criteria become the new current criteria. However, posttransplant outcomes for patients with very high MELD scores and patients with HCV/HIV coinfections are increasingly under scrutiny, and there have been suggestions of restricting transplantation in these groups.

Table 4. Can We Trek New Ground?
CategoryTrekking New Ground?
General indicationsPatients with low MELD scores (Berg et al.10)
Perhaps the exclusion of patients with very high MELD scores (Weismüller et al.11 and Quante et al.12)
Improvements in nutrition/muscle strength
Age>70 years (perhaps non-HCC patients; Keswani et al.17)
HCCHow far beyond the Milan criteria should we go (Clavien et al.,22 Germani et al.23)?
Non-HCC malignancyNew selection criteria for cholangiocarcinoma and neuroendocrine tumors (Nguyen et al.,25 Rosen et al.,26 Murad et al.,27 Panjala et al.,28 Hong et al.29)
PPHTreatment to reduce PAP to <40 mm Hg (Ramsay,30 Hollatz et al.31)
HPSPaO2 < 50 mm Hg but shunt < 20% (Arguedas et al.33)
ALDAlcoholic hepatitis (Mathurin et al.35)
HIVHIV viremic control only after transplantation
What should be done about HCV/HIV-coinfected patients
Structural nonhepatic diseaseCAD, stents, concurrent surgery, and combined transplantation (Carey et al.,42 Plotkin et al.,43 Findlay,44 Raval et al.,45 Ehtisham et al.,46 Azarbal et al.,47 Raichlin et al.,48 Gardner and Gibbs,49 Torregrosa et al.,50 Bravo and Hage,51 and Hennessey et al.52)
Socioeconomic/psychosocialWritten policies and patient advocates (Volk et al.58)
Narcotic addictionNonexclusion of methadone maintenance patients (Koch et al.60)

REFERENCES

  1. Top of page
  2. Abstract
  3. EXTENDED CRITERIA IN THE UNCOMPLICATED PATIENT
  4. EXTENDED CRITERIA FOR AGE
  5. EXTENDED CRITERIA FOR HCC
  6. EXTENDED CRITERIA FOR NON-HCC HEPATIC MALIGNANCIES
  7. EXTENDED CRITERIA FOR PPH AND HPS
  8. EXTENDED CRITERIA FOR ALD
  9. EXTENDED CRITERIA FOR HIV INFECTIONS
  10. EXTENDED CRITERIA FOR STRUCTURAL NONHEPATIC DISEASE [PARTICULARLY CORONARY ARTERY DISEASE (CAD)]
  11. EXTENDED SOCIOECONOMIC CRITERIA
  12. EXTENDED CRITERIA FOR NARCOTIC ADDICTION
  13. SUMMARY AND CONCLUSIONS: HOW CAN WE OVERCOME THESE IMPEDIMENTS AND BARRIERS FOR EXTENDED CRITERIA PATIENTS?
  14. REFERENCES
  • 1
    Murray KF, Carithers RL Jr; for AASLD. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005; 41: 1407-1432.
  • 2
    Transplantation Society of Australia and New Zealand. Organ transplantation from deceased donors: consensus statement on eligibility criteria and allocation protocols. http://www.tsanz.com.au/downloads/201123June-TSANZConsensusStatementVs1.1.pdf. Accessed July 2012.
  • 3
    Scientific Registry of Transplant Recipients. http://www.srtr.org. Accessed July 2012.
  • 4
    European Liver Transplant Registry. http://www.eltr.org. Accessed July 2012.
  • 5
    Australia & New Zealand Liver Transplant Registry. http://www.anzltr.org. Accessed July 2012.
  • 6
    Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. Am J Transplant 2005; 5: 307-313.
  • 7
    Schaubel DE, Wolfe RA, Sima CS, Merion RM. Estimating the effect of a time-dependent treatment by levels of an internal time-dependent covariate: application to the contrast between liver wait-list and post-transplant mortality. J Am Stat Assoc 2009; 104: 49-59.
  • 8
    Sharma P, Schaubel DE, Guidinger MK, Merion RM. Effect of pretransplant serum creatinine on the survival benefit of liver transplantation. Liver Transpl 2009; 15: 1808-1813.
  • 9
    Schaubel DE, Sima CS, Goodrich NP, Feng S, Merion RM. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 2008; 8: 419-425.
  • 10
    Berg CL, Merion RM, Shearon TH, Olthoff KM, Brown RS Jr, Baker TB, et al. Liver transplant recipient survival benefit with living donation in the Model for Endstage Liver Disease allocation era. Hepatology 2011; 54: 1313-1321.
  • 11
    Weismüller TJ, Fikatas P, Schmidt J, Barreiros AP, Otto G, Beckebaum S, et al. Multicentric evaluation of Model for End-Stage Liver Disease-based allocation and survival after liver transplantation in Germany—limitations of the 'sickest first'-concept. Transpl Int 2011; 24: 91-99.
  • 12
    Quante M, Benckert C., Thelen A., Gabelein G., Bercker S., Kaisers U., Berg T., Jonas S. Five-year-experience with high-MELD recipients (>30 points)—single-centre results and re-evaluation of prognostic models for postoperative survival. Paper presented at: 24th International Congress of the Transplantation Society; July 15-19, 2012; Berlin, Germany.
  • 13
    Sam J, Nguyen GC. Protein-calorie malnutrition as a prognostic indicator of mortality among patients hospitalized with cirrhosis and portal hypertension. Liver Int 2009; 29: 1396-1402.
  • 14
    Gunsar F, Raimondo ML, Jones S, Terreni N, Wong C, Patch D, et al. Nutritional status and prognosis in cirrhotic patients. Aliment Pharmacol Ther 2006; 24: 563-572.
  • 15
    Tandon P, Ney M, Irwin I, Ma MM, Gramlich L, Bain VG, et al. Severe muscle depletion in patients on the liver transplant wait list—its prevalence and independent prognostic value. Liver Transpl; doi:10.1002/lt.23495.
  • 16
    Jones JC, Coombes JS, Macdonald GA. Exercise capacity and muscle strength in patients with cirrhosis. Liver Transpl 2012; 18: 146-151.
  • 17
    Keswani RN, Ahmed A, Keeffe EB. Older age and liver transplantation: a review. Liver Transpl 2004; 10: 957-967.
  • 18
    Lipshutz GS, Hiatt J, Ghobrial RM, Farmer DG, Martinez MM, Yersiz H, et al. Outcome of liver transplantation in septuagenarians: a single-center experience. Arch Surg 2007; 142: 775-781.
  • 19
    Aloia TA, Knight R, Gaber AO, Ghobrial RM, Goss JA. Analysis of liver transplant outcomes for United Network for Organ Sharing recipients 60 years old or older identifies multiple Model for End-Stage Liver Disease-independent prognostic factors. Liver Transpl 2010; 16: 950-959.
  • 20
    Schwartz JJ, Pappas L, Thiesset HF, Vargas G, Sorensen JB, Kim RD, et al. Liver transplantation in septuagenarians receiving Model for End-Stage Liver Disease exception points for hepatocellular carcinoma: the national experience. Liver Transpl 2012; 18: 423-433.
  • 21
    Perkins JD. Treatment of an elderly patient with hepatocellular carcinoma: counseling from the patient's point of view. Liver Transpl 2012; 18: 391-394.
  • 22
    Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A; for OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13: e11-e22.
  • 23
    Germani G, Gurusamy K, Garcovich M, Toso C, Fede G, Hemming A, et al. Which matters most: number of tumors, size of the largest tumor, or total tumor volume? Liver Transpl 2011; 17( suppl 2): S58-S66.
  • 24
    Schlitt HJ, Mornex F, Shaked A, Trotter JF. Immunosuppression and hepatocellular carcinoma. Liver Transpl 2011; 17( suppl 2): S159-S161.
  • 25
    Nguyen NT, Harring TR, Goss JA, O'Mahony CA. Neuroendocrine liver metastases and orthotopic liver transplantation: the US experience. Int J Hepatol 2011; 2011: 742890.
  • 26
    Rosen CB, Heimbach JK, Gores GJ. Liver transplantation for cholangiocarcinoma. Transpl Int 2010; 23: 692-697.
  • 27
    Murad SD, Kim WR, Therneau T, Gores GJ, Rosen CB, Martenson JA, et al. Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology; doi:10.1002/hep.25629.
  • 28
    Panjala C, Nguyen JH, Al-Hajjaj AN, Rosser BA, Nakhleh RE, Bridges MD, et al. Impact of neoadjuvant chemoradiation on the tumor burden before liver transplantation for unresectable cholangiocarcinoma. Liver Transpl 2012; 18: 594-601.
  • 29
    Hong JC, Jones CM, Duffy JP, Petrowsky H, Farmer DG, French S, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch Surg 2011; 146: 683-689.
  • 30
    Ramsay M. Pulmonary hypertension and liver transplantation. In: Milan Z, ed. Cardiovascular Diseases and Liver Transplantation. New York, NY: Nova Science Publishers; 2011: 83-97.
  • 31
    Hollatz TJ, Musat A, Westphal S, Decker C, D'Alessandro AM, Keevil J, et al. Treatment with sildenafil and treprostinil allows successful liver transplantation of patients with moderate to severe portopulmonary hypertension. Liver Transpl 2012; 18: 686-695.
  • 32
    Fauconnet P, Ho V, Pastor C, Schiffer E. Hepatopulmonary syndrome. In: Milan Z, ed. Cardiovascular Diseases and Liver Transplantation. New York, NY: Nova Science Publishers; 2011: 179-192.
  • 33
    Arguedas MR, Abrams GA, Krowka MJ, Fallon MB. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. Hepatology 2003; 37: 192-197.
  • 34
    Lucey MR. Liver transplantation in patients with alcoholic liver disease. Liver Transpl 2011; 17: 751-759.
  • 35
    Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011; 365: 1790-1800.
  • 36
    Terrault NA, Roland ME, Schiano T, Dove L, Wong MT, Poordad F, et al.; for Solid Organ Transplantation in HIV: Multi-Site Study Investigators. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl 2012; 18: 716-726.
  • 37
    Duclos-Vallée JC, Féray C, Sebagh M, Teicher E, Roque-Afonso AM, Roche B, et al.; for THEVIC Study Group. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008; 47: 407-417.
  • 38
    Barshes NR, DiBardino DJ, McKenzie ED, Lee TC, Stayer SA, Mallory GB, et al. Combined lung and liver transplantation: the United States experience. Transplantation 2005; 80: 1161-1167.
  • 39
    Wyatt K, et al. Reducing the load: the evolution and management of obesity and nonalcoholic steatohepatitis before liver transplantation. Liver Transpl 2012; 18.
  • 40
    Charlton MR, Wall WJ, Ojo AO, Ginès P, Textor S, Shihab FS, et al.; for International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl 2009; 15: S1-S34.
  • 41
    Møller S, Henriksen JH. Haemodynamic profile of patients with end-stage liver disease. In: Milan Z, ed. Cardiovascular Diseases and Liver Transplantation. New York, NY: Nova Science Publishers; 2011: 1-30.
  • 42
    Carey WD, Dumot JA, Pimentel RR, Barnes DS, Hobbs RE, Henderson JM, et al. The prevalence of coronary artery disease in liver transplant candidates over age 50. Transplantation 1995; 59: 859-864.
  • 43
    Plotkin JS, Scott VL, Pinna A, Dobsch BP, De Wolf AM, Kang Y. Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver transplantation. Liver Transpl Surg 1996; 2: 426-430.
  • 44
    Findlay JY. Coronary artery disease and liver transplantation. In: Milan Z, ed. Cardiovascular Diseases and Liver Transplantation. New York, NY: Nova Science Publishers; 2011: 31-48.
  • 45
    Raval Z, Harinstein ME, Skaro AI, Erdogan A, DeWolf AM, Shah SJ, et al. Cardiovascular risk assessment of the liver transplant candidate. J Am Coll Cardiol 2011; 58: 223-231.
  • 46
    Ehtisham J, Altieri M, Salamé E, Saloux E, Ollivier I, Hamon M. Coronary artery disease in orthotopic liver transplantation: pretransplant assessment and management. Liver Transpl 2010; 16: 550-557.
  • 47
    Azarbal B, Poommipanit P, Arbit B, Hage A, Patel J, Kittleson M, et al. Feasibility and safety of percutaneous coronary intervention in patients with end-stage liver disease referred for liver transplantation. Liver Transpl 2011; 17: 809-813.
  • 48
    Raichlin E, Rosen CB, Dumitru I, Daly RC, Kushwaha SS. Combined cardiac surgery and liver transplantation. In: Milan Z, ed. Cardiovascular Diseases and Liver Transplantation. New York, NY: Nova Science Publishers; 2011: 139-158.
  • 49
    Gardner AI, Gibbs NM. Valvular heart disease and liver transplantation. In: Milan Z, ed. Cardiovascular Diseases and Liver Transplantation. New York, NY: Nova Science Publishers; 2011: 67-81.
  • 50
    Torregrosa M, Aguadé S, Dos L, Segura R, Gónzalez A, Evangelista A, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 2005; 42: 68-74.
  • 51
    Bravo PE, Hage FG. Hypertrophic obstructive cardiomyopathy in liver transplant patients. In: Milan Z, ed. Cardiovascular Diseases and Liver Transplantation. New York, NY: Nova Science Publishers; 2011: 99-112.
  • 52
    Hennessey T, Backman SB, Cecere R, Lachapelle K, de Varennes B, Ergina P, et al. Combined heart and liver transplantation on cardiopulmonary bypass: report of four cases. Can J Anaesth 2010; 57: 355-360.
  • 53
    Kemmer N, Zacharias V, Kaiser TE, Neff GW. Access to liver transplantation in the MELD era: role of ethnicity and insurance. Dig Dis Sci 2009; 54: 1794-1797.
  • 54
    Kemmer N, Neff GW. Liver transplantation in the ethnic minority population: challenges and prospects. Dig Dis Sci 2010; 55: 883-889.
  • 55
    Yoo HY, Galabova V, Edwin D, Thuluvath PJ. Socioeconomic status does not affect the outcome of liver transplantation. Liver Transpl 2002; 8: 1133-1137.
  • 56
    Hunt CM, Tart JS, Dowdy E, Bute BP, Williams DM, Clavien PA. Effect of orthotopic liver transplantation on employment and health status. Liver Transpl Surg 1996; 2: 148-153.
  • 57
    Verna EC, Valadao R, Farrand E, Pichardo EM, Lai JC, Terrault NA, Brown RS Jr. Effects of ethnicity and socioeconomic status on survival and severity of fibrosis in liver transplant recipients with hepatitis C virus. Liver Transpl 2012; 18: 461-467.
  • 58
    Volk ML, Biggins SW, Huang MA, Argo CK, Fontana RJ, Anspach RR. Decision making in liver transplant selection committees: a multicenter study. Ann Intern Med 2011; 155: 503-508.
  • 59
    Hogan BE, Linden W, Najarian B. Social support interventions: do they work? Clin Psychol Rev 2002; 22: 383-442.
  • 60
    Koch M, Banys P. Methadone is a medication, not an addiction. Liver Transpl 2002; 8: 783-786.
  • 61
    Jiao M, Greanya ED, Haque M, Yoshida EM, Soos JG. Methadone maintenance therapy in liver transplantation. Prog Transplant 2010; 20: 209-214.
  • 62
    Kanchana TP, Kaul V, Manzarbeitia C, Reich DJ, Hails KC, Munoz SJ, Rothstein KD. Liver transplantation for patients on methadone maintenance. Liver Transpl 2002; 8: 778-782.
  • 63
    Liu LU, Schiano TD, Lau N, O'Rourke M, Min AD, Sigal SH, et al. Survival and risk of recidivism in methadone-dependent patients undergoing liver transplantation. Am J Transplant 2003; 3: 1273-1277.
  • 64
    Weinrieb RM, Barnett R, Lynch KG, DePiano M, Atanda A, Olthoff KM. A matched comparison study of medical and psychiatric complications and anesthesia and analgesia requirements in methadone-maintained liver transplant recipients. Liver Transpl 2004; 10: 97-106.
  • 65
    Hancock MM, Craemer EM, Rossaro L. Liver transplantation and methadone. http://www.hcvadvocate.org/hcsp/articles/Methadone_transplant.html. Accessed July 2012.